Search results for "REDUCTASE"

showing 10 items of 798 documents

A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions

2018

Aims: The clinical value of percutaneous coronary intervention (PCI) for chronic coronary total occlusions (CTOs) is not established by randomized trials. This study should compare the benefit of PCI vs. optimal medical therapy (OMT) on the health status in patients with at least one CTO.Method and results: Three hundred and ninety-six patients were enrolled in a prospective randomized, multicentre, open-label, and controlled clinical trial to compare the treatment by PCI with OMT with a 2:1 randomization ratio. The primary endpoint was the change in health status assessed by the Seattle angina questionnaire (SAQ) between baseline and 12 months follow-up. Fifty-two percent of patients have …

Malemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyAngina Pectorislaw.inventionAngina03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineClinical endpointHumansPercutaneous transluminal interventioncardiovascular diseases030212 general & internal medicineMyocardial infarctionOptimal medical therapyAgedNitratesbusiness.industryAngina PectoriPercutaneous coronary interventionAngiotensin-Converting Enzyme InhibitorMiddle Agedmedicine.diseaseClinical trialCoronary OcclusionChronic coronary occlusion; EQ-5D; Optimal medical therapy; Percutaneous transluminal intervention; Seattle angina questionnaire; Cardiology and Cardiovascular MedicineConventional PCIChronic DiseaseChronic coronary occlusionQuality of LifeSeattle angina questionnaireFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitors
researchProduct

Benefits of Statin Therapy Based on Plasma Carbohydrate Antigen 125 Values Following an Admission for Acute Heart Failure

2011

The prognostic benefit of statins in patients with heart failure is a topic of controversy. Under the hypothesis that statins may provide greater benefit in a subgroup of patients with heightened inflammatory activity, we sought to explore whether statins are associated with a decreased risk of long-term mortality in patients with acute heart failure based on elevated levels of carbohydrate antigen 125, a biomarker related to systemic congestion and proinflammatory status.We analysed 1222 consecutive patients admitted with acute heart failure in a single teaching center during a median follow-up of 20 months. carbohydrate antigen 125 was measured during index hospitalization and dichotomize…

Malemedicine.medical_specialtyRisk AssessmentProinflammatory cytokineCohort StudiesElectrocardiographyCause of DeathInternal medicinemedicineHumansProspective StudiesIntensive care medicineProspective cohort studyAgedCause of deathAged 80 and overHeart Failuremedicine.diagnostic_testbusiness.industryGeneral MedicineMiddle AgedPrognosismedicine.diseaseCardiovascular DiseasesCA-125 AntigenHeart failureAcute DiseaseBiomarker (medicine)FemaleHydroxymethylglutaryl-CoA Reductase InhibitorsRisk assessmentbusinessElectrocardiographyBiomarkersFollow-Up StudiesCohort studyRevista Española de Cardiología (English Edition)
researchProduct

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

2015

BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy.METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaIntention to Treat AnalysiHypercholesterolemiaUrologyalirocumabBococizumabPharmacologyPlaceboAged; Antibodies Monoclonal; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Drug Therapy Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intention to Treat Analysis; Male; Middle Aged; Medicine (all)law.inventionchemistry.chemical_compoundcardiovascular eventsDouble-Blind MethodRandomized controlled triallawCardiovascular DiseaseAnticholesteremic AgentMedicineproprotein convertase subtilisin–kexin type 9 (PCSK9)High Cardiovascular Risk PatientsAgedAlirocumabalirocumab; cholesterol; cardiovascular eventsCholesterolbusiness.industryMedicine (all)PCSK9Antibodies MonoclonalcholesterolCholesterol LDLGeneral MedicineMiddle AgedLomitapideEvolocumabchemistrylow-density lipoprotein (LDL) cholesterol[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorbusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHumanNew England journal of medicine
researchProduct

Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins

2007

The receptor for advanced glycation endproducts (RAGE) is overexpressed at sites of vascular pathology. A soluble RAGE isoform (sRAGE) neutralizes the ligand-mediated damage by acting as a decoy. We hypothesized that in hypercholesterolemia up-regulation of the ligand-RAGE axis may bridge impairment of nitric oxide biosynthesis with oxidative stress. We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (ADMA). The effects of two structurally different statins (pravastatin and atorvastatin) on these parameters were analyzed in 20 hypercholesterolemic su…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaStatinmedicine.drug_classAtorvastatinHypercholesterolemiaReceptor for Advanced Glycation End ProductsFree radicalsArginineDinoprostNitric Oxidemedicine.disease_causeBiochemistrychemistry.chemical_compoundDouble-Blind MethodPhysiology (medical)Internal medicineHyperlipidemiaAtorvastatinmedicineHumansPyrrolesReceptors ImmunologicEndothelial dysfunctionPravastatinChemistryVascular diseaseAnticholesteremic AgentsStatinnutritional and metabolic diseasesMiddle AgedAtherosclerosismedicine.diseaseADMACross-Sectional StudiesHyperlipidemiaEndocrinologyHeptanoic AcidsOxidative streFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsNitric Oxide SynthaseAsymmetric dimethylarginineOxidative stressPravastatinsRAGEmedicine.drugFree Radical Biology and Medicine
researchProduct

Mitochondrial myopathy with lactic acidosis and deficient activity of muscle succinate cytochrome-c-oxidoreductase

1984

A male infant had severe muscular hypotonia from birth. Recurrent vomiting with dehydration and severe metabolic acidosis complicated the course. Elevated lactate (up to 12.3 mmol/l; n less than 2), pyruvate (0.4 mmol/l; n less than 0.05) and alanine levels were found in serum with an abnormal lactate/pyruvate ratio (greater than 30; n less than 15). In urine the concentrations of lactate, pyruvate, alanine and of several intermediates of the citric acid cycle were increased. In muscle, numerous disseminated "ragged red fibres" were found by light microscopy; muscle fibres were found to contain subsarcolemmal aggregates of mitochondria, lipid droplets and glycogen by electromicroscopical me…

Malemedicine.medical_specialtySevere muscular hypotoniaRespiratory chainMitochondria Livermacromolecular substancesMitochondrionBiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMuscular DiseasesMitochondrial myopathy030225 pediatricsInternal medicinemedicineHumansGlycogenMusclesInfantMetabolic acidosismedicine.diseaseMitochondriaMitochondria Muscle3. Good healthCitric acid cycleEndocrinologyBiochemistrychemistryLactic acidosisPediatrics Perinatology and Child HealthLactatesSuccinate Cytochrome c OxidoreductaseAcidosisOxidoreductases030217 neurology & neurosurgeryEuropean Journal of Pediatrics
researchProduct

Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and …

2009

Abstract Background Effects independent from cholesterol reduction on vascular function are considered to importantly contribute to the beneficial effects of statin therapy in cardiovascular disease. We aimed to evaluate the effect of high versus low dose atorvastatin on endothelial dysfunction in patients with coronary artery disease (CAD) in a setting of comparable cholesterol reduction. Methods and results Fifty-eight patients with CAD were randomly assigned to double-blind treatment for 8 weeks with atorvastatin 80mg per day (A80) or atorvastatin 10mg+ezetimibe 10mg per day (A10E10), respectively. Flow-mediated vasodilation (FMD) of the brachial artery, nitroglycerin-mediated endotheliu…

Malemedicine.medical_specialtyStatinmedicine.drug_classAtorvastatinCoronary Artery DiseaseCoronary artery diseasechemistry.chemical_compoundEzetimibeDouble-Blind Methodmedicine.arteryInternal medicinemedicineAtorvastatinHumansPyrrolescardiovascular diseasesEndothelial dysfunctionBrachial arteryAgedbiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLMiddle Agedmedicine.diseaseAtherosclerosisEzetimibeEndocrinologyC-Reactive ProteinCholesterolTreatment OutcomechemistryHeptanoic AcidsHMG-CoA reductaseCardiologybiology.proteinAzetidineslipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugAtherosclerosis
researchProduct

Statin Use and Knee Osteoarthritis Outcomes: A Longitudinal Cohort Study

2018

Objective: Statins have several pleiotropic effects, but the literature regarding the possible relationship between use of statins and outcomes in knee osteoarthritis (OA) is limited. The aim of this study was to investigate whether statin use is associated with a lower risk of radiographic OA (ROA), radiographic symptomatic knee OA, and pain in North American individuals. Methods: A total of 4,448 community-dwelling adults from the Osteoarthritis Initiative were followed for 4 years. Statin use (including the time from baseline and the type of statin) was defined through self-report information and confirmed by a trained interviewer. Knee OA outcomes included incident ROA, symptomatic knee…

Malemedicine.medical_specialtyStatinmedicine.drug_classAtorvastatinPROGRESSIONOsteoarthritisLower riskTHERAPYArticleCohort Studies03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinemedicineHumansEPIDEMIOLOGYRosuvastatinLongitudinal StudiesSCALEAgedddc:616030203 arthritis & rheumatologyRISKbusiness.industryIncidencenutritional and metabolic diseasesMiddle AgedOsteoarthritis Kneemedicine.diseaseDEPRESSIONRHEUMATOID-ARTHRITISKnee painRelative riskFemalemedicine.symptomHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessmedicine.drugCohort study
researchProduct

Should low high-density lipoprotein cholesterol (HDL-C) be treated?

2014

The first observations linking a low serum level of HDL-C to increased risk for cardiovascular disease were made over 50 years ago. High serum levels of HDL-C appear to protect against the development of atherosclerotic disease, while low serum levels of this lipoprotein are among the most important predictors of atherosclerotic disease in both men and women and people of all racial and ethnic groups throughout the world. It has long been assumed that therapeutic interventions targeted at raising HDL-C levels would lower risk for such cardiovascular events as myocardial infarction, ischemic stroke, and death. Even after five decades of intensive investigation, evidence to support this assum…

Malemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismDiseaseLower riskNiacinlaw.inventionCoronary artery diseaseEndocrinologyRandomized controlled triallawRisk FactorsInternal medicinemedicineHumansMyocardial infarctionDyslipidemiasbusiness.industryReverse cholesterol transportCholesterol HDLFibric Acidsmedicine.diseaseEndocrinologyCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleThiazolidinedionesHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinesscoronary artery disease fibrate high-density lipoproteins low-density lipoproteins niacin reverse cholesterol transport statin thiazolidinedioneNiacin
researchProduct

Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion.

2002

Abstract Background: Beneath its lipid-lowering properties additional non-lipid effects of statin therapy are discussed. We therefore examined the impact of statins on laboratory markers of coagulation, inflammation and soluble cell adhesion to further explore these effects in 950 hospitalised patients with angiographically proven CAD. Methods and results: Although no significant differences were found in total cholesterol, LDL and HDL and triglyceride levels a statistically lower value in 277 statin-treated patients was found for von Willebrand factor [162(130/224) vs. 208(154/283)%, P =0.0001], leukocyte count [6.9(5.8/8.4) vs. 7.3(6.1/9.4)/nl, P =0.0005], high sensitive CRP [4.3(1.8/10.8…

Malemedicine.medical_specialtyStatinmedicine.drug_classInflammationCoronary Artery DiseaseSystemic inflammationchemistry.chemical_compoundVon Willebrand factorInternal medicinevon Willebrand FactormedicineCell AdhesionHumansAgedbiologyTriglycerideCholesterolbusiness.industryAnticholesteremic AgentsCholesterol LDLMiddle AgedEndocrinologyCoagulationchemistryHMG-CoA reductasebiology.proteinFemalemedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkersInternational journal of cardiology
researchProduct

Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials

2013

The available data on statin effects in chronic kidney disease (CKD) patients are still conflicting. We investigated the impact of short- and long-term statin therapy on lipid profiles in CKD patients requiring or not requiring dialysis.Data from Scopus, PubMed, Web of Science, and the Cochrane Library from 1966 to May 2012 were searched for studies that investigated this effect. We included all randomized controlled clinical trials that investigated the impact of statin therapy on lipids and lipoproteins.The final analysis included 16 trials with 3594 subjects. In CKD patients, statin therapy significantly reduced total cholesterol (TC), triglycerides (TG) and low-density lipoprotein chole…

Malemedicine.medical_specialtyStatinmedicine.drug_classmedicine.medical_treatmentCochrane LibraryPharmacologylaw.inventionRandomized controlled trialRenal DialysislawInternal medicinemedicineHumansRenal Insufficiency ChronicCholesterol Chronic kidney disease Dialysis Hemodialysis Lipids Lipoproteins Meta-analysis StatinsDialysisRandomized Controlled Trials as Topicmedicine.diagnostic_testbusiness.industryGeneral Medicinemedicine.diseaseLipidsClinical trialFemalelipids (amino acids peptides and proteins)HemodialysisHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profilebusinessKidney diseaseCurrent Medical Research and Opinion
researchProduct